Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ELVNthis companyEnliven Therapeutics, Inc.	$50.90	-8.42×	1.9×	0×	-7.48×	-96.2%	0.0%	0.0%	0.0%	-22.6%	-26.0%	-8.1%	0×	0.95×	0×	28.66×	0.0%	2	130.13	2	C+
AVBPArriVent BioPharma, Inc.	$14.54	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
CGEMCullinan Therapeutics, Inc.	$11.61	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
EXELExelixis, Inc.	$71.55	15.13×	5.48×	5.1×	12.5×	124.2%	96.4%	37.6%	33.7%	36.2%	29.7%	7.1%	0.08×	-0.34×	0×	3.56×	0.0%	6	18.06	4	A
INCYIncyte Corporation	$120.91	14.99×	3.73×	3.75×	9.23×	-2.4%	92.8%	26.1%	25.0%	24.9%	20.6%	7.0%	0.01×	-1.72×	553.04×	3.32×	0.0%	6	10.87	3	B+
NUVBNuvation Bio Inc.	$4.32	-14.93×	10.01×	48.65×	-15.36×	-33.1%	86.6%	-338.7%	-325.3%	-66.9%	-41.0%	-5.7%	0.03×	0.81×	-15.57×	6.95×	0.0%	3	0.52	1	C-
Peer median	—	-2.78×	3.73×	3.75×	-2.39×	-33.1%	86.6%	0.0%	0.0%	-53.8%	-41.0%	-5.7%	0.01×	0.27×	0×	6.95×	0.0%	3	10.87	2	—